Search
Remibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigationalThe FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.
Zanidatamab
go.drugbank.com/drugs/DB15471ApprovedInvestigationalZanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2).
Synonyms: SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPPEtofenamate
go.drugbank.com/drugs/DB08984InvestigationalEtofenamate is used to treat muscle and joint paint. It is a non-steroidal anti-inflammatory drug (NSAID).
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSBendamustine
go.drugbank.com/drugs/DB06769ApprovedInvestigationalBendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). … Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules.
Green tea leaf
go.drugbank.com/drugs/DB14307InvestigationalIt is not an approved drug.
Mixtures: GONGFUTOUTANG Tou Tang Powder No. 3Synonyms: Camelliae Sinensis Non Fermentatum FoliumAgmatine
go.drugbank.com/drugs/DB08838ExperimentalUp to now (July 2013), the results of this study have not yet been published. … It is formed when arginine is decarboxylated by the enzyme arginine decarboxylase and is found naturally in ragweed pollen, ergot fungi, octopus muscle, herring sperm, sponges, and the mammalian brain.
Synonyms: N-(4-aminobutyl)guanidineAmbrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalIn addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. … It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening.
REP8839
go.drugbank.com/drugs/DB05224ExperimentalREP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).